The government has placed orders for import of 4.5 lakh (450,000) vials of antiviral drug Remdesivir with the first consignment of 75,000 vials expected to reach Indian shores on Friday, Chemicals and Fertilisers Ministry said in a statement.
The government has started importing the vital drug from other countries to ease its shortage in the country, it said.
The first consignment of 75,000 vials will reach India on Friday, it added.
Demand for Remdesivir has gone up manifold in the country with a surge in COVID-19 cases.
The antiviral drug is being used in the treatment of infectious disease.
HLL Lifecare Ltd, a Government of India owned company has ordered 4,50,000 vials of Remdesivir from M/s Gilead Sciences Inc USA and Egyptian Pharma Company, M/s Eva Pharma, the release said.
It is expected that Gilead Sciences will dispatch 75,000 to 1,00,000 vials in the next one or two days, it noted.
Further one lakh vials will also be supplied before or by May 15, the release said.
EVA Pharma will supply around 10,000 vials initially followed by 50,000 vials every 15 days or till July, it added.
The Chemicals and Fertilisers Ministry said it has also ramped up the production capacity of Remdesivir in the country.
As on April 27, the production capacity of the seven licensed domestic manufacturers has increased from 38 lakh vials per month to 1.03 crore vials per month, it said.
Besides, a total 13.73 lakh vials have been supplied across the country by the drug companies in the last seven days (April 21-28). The daily supply has gone up from 67,900 vials on April 11 to 2.09 lakh vials on April 28, it added.
An advisory was also issued by Ministry of Home Affairs to states and union territories to facilitate smooth movement of Remdesivir supplies, the ministry noted.
The government has also taken various steps, like ban on exports and customs duty waiver, to enhance the availability of Remdesivir in the country, it said.
India saw 3,86,452 new coronavirus infections in a span of 24 hours, the highest single-day rise so far, pushing the total tally of COVID-19 cases to 1,87,62,976, while active cases crossed the 31-lakh mark.
The death toll increased to 2,08,330 with 3,498 new fatalities, as per the Union health ministry data.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)